Karyopharm's SENTRY Trial Achieves Highly Significant Myelofibrosis Benefit
KPTI has more than doubled off its 52-week low of $3.65.
Summary
Karyopharm Therapeutics announced highly positive Phase 3 SENTRY trial results for selinexor+ruxolitinib in myelofibrosis, demonstrating a statistically significant improvement in SVR35 (50% vs 28%, P<0.0001) and a favorable OS HR of 0.43. This significant clinical advancement provides a critical positive catalyst for the company. While Karyopharm recently reported Q1 2026 financials (revenue $35.1M, EPS -$1.24) and confirmed a going concern warning with a short cash runway until late Q3 2026, these new trial results were not previously disclosed. The strong efficacy data could substantially de-risk Karyopharm's pipeline and significantly improve its financial outlook, potentially facilitating new funding or partnerships. This positive development is particularly impactful for a company of Karyopharm's size facing liquidity concerns. Investors will now closely monitor regulatory next steps for selinexor in myelofibrosis and the company's strategy to leverage these results to address its going concern warning and secure long-term funding.
At the time of this announcement, KPTI was trading at $8.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $200.6M. The 52-week trading range was $3.65 to $10.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.